Literature DB >> 11948013

17beta-Estradiol inhibits cytokine induction of the human E-selectin promoter.

Curtis M Tyree1, Aihua Zou, Elizabeth A Allegretto.   

Abstract

Estradiol has been shown to decrease levels of the cell adhesion molecule E-selectin in cultured cells and in women on hormone replacement therapy. We set out to determine if the mechanism of estradiol action on E-selectin is at the level of its promoter. It was found that estradiol repressed the cytokine-stimulated induction of luciferase activity driven by the human E-selectin promoter in a reporter plasmid (hE-sel-LUC) in co-transfected human hepatoma cells (Hep G2) and human umbilical cord endothelial cells (ECV-304). Repression by estradiol was dependent on the presence of transfected estrogen receptor (ER) alpha or beta expression vectors. The ER antagonist ICI-182,780 blocked the repression by estradiol, confirming the receptor-dependence of the effect. The intact DNA-binding domain of ERalpha was required for estradiol repression of the cytokine-induced stimulation of the promoter in each cell line as demonstrated by the inability of an ER construct with two point mutations in the DNA-binding domain to inhibit reporter activity. Mutation of the NFK-B site at -94 to -85 within the E-selectin promoter led to less stimulation of hE-sel-LUC by interleukin one beta (IL-1beta). Estradiol did not inhibit this IL-1beta stimulated luciferase activity, indicating that the NFK-B site is necessary for ER-mediated inhibition of this promoter. Mutation of the AP-1 site at -500 to -494 within the E-selectin promoter had no effect on the ability of IL-1beta to stimulate its transcription, and estradiol repressed this activation in an ER-dependent manner with identical efficacy and potency in comparison with the wild-type promoter. Therefore, the E-selectin promoter is down-regulated by estradiol working through either ERalpha or ERbeta and requires the NFK-B site at -94 to -85 within the promoter.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948013     DOI: 10.1016/s0960-0760(02)00022-5

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

Review 1.  The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease.

Authors:  M Elizabeth Moss; Brigett Carvajal; Iris Z Jaffe
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

2.  Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.

Authors:  Christopher C Chadwick; Susan Chippari; Edward Matelan; Lisa Borges-Marcucci; Amy M Eckert; James C Keith; Leo M Albert; Yelena Leathurby; Heather A Harris; Ramesh A Bhat; Mark Ashwell; Eugene Trybulski; Richard C Winneker; Steven J Adelman; Robert J Steffan; Douglas C Harnish
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

3.  Estradiol is associated with mortality in critically ill trauma and surgical patients.

Authors:  Addison K May; Lesly A Dossett; Patrick R Norris; Erik N Hansen; Randalyn C Dorsett; Kimberley A Popovsky; Robert G Sawyer
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

4.  Targeting estrogen receptor β in microglia and T cells to treat experimental autoimmune encephalomyelitis.

Authors:  Wan-fu Wu; Xin-jie Tan; Yu-bing Dai; Venkatesh Krishnan; Margaret Warner; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

Review 5.  The aryl hydrocarbon receptor complex and the control of gene expression.

Authors:  Timothy V Beischlag; J Luis Morales; Brett D Hollingshead; Gary H Perdew
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

6.  Inflammatory status influences aromatase and steroid receptor expression in endometriosis.

Authors:  Orhan Bukulmez; Daniel B Hardy; Bruce R Carr; R Ann Word; Carole R Mendelson
Journal:  Endocrinology       Date:  2007-11-29       Impact factor: 4.736

Review 7.  The silent estrogen receptor--can we make it speak?

Authors:  Madhavi Billam; Abigail E Witt; Nancy E Davidson
Journal:  Cancer Biol Ther       Date:  2009-03-15       Impact factor: 4.742

8.  The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis.

Authors:  James C Keith; Leo M Albert; Yelena Leathurby; Max Follettie; Lili Wang; Lisa Borges-Marcucci; Christopher C Chadwick; Robert J Steffan; Douglas C Harnish
Journal:  Arthritis Res Ther       Date:  2005-02-21       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.